Holen Sie sich die Stockscreener-App
1.94
5.37%
-0.11
Handel nachbörslich:
1.95
0.01
+0.52%
Schlusskurs vom Vortag:
$2.05
Offen:
$2.09
24-Stunden-Volumen:
2.56M
Relative Volume:
9.19
Marktkapitalisierung:
$14.16M
Einnahmen:
$1.98M
Nettoeinkommen (Verlust:
$-9.63M
KGV:
-1.099
EPS:
-1.7653
Netto-Cashflow:
$-9.76M
1W Leistung:
-74.41%
1M Leistung:
-76.14%
6M Leistung:
-39.38%
1J Leistung:
-35.55%
1-Tages-Spanne:
$1.9029
$2.10
1-Wochen-Bereich:
$1.81
$9.2999
52-Wochen-Spanne:
$1.81
$12.37
Lipocine Inc Stock (LPCN) Company Profile
Firmenname
Lipocine Inc
Sektor
Branche
Telefon
801 994 7383
Adresse
675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY, UT
Compare LPCN vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LPCN
Lipocine Inc
|
1.94 | 14.96M | 1.98M | -9.63M | -9.76M | -1.7653 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Lipocine Inc Stock (LPCN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-06-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-12-10 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2018-01-12 | Bestätigt | H.C. Wainwright | Buy |
| 2018-01-11 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2017-12-08 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-10-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-07-22 | Eingeleitet | ROTH Capital | Buy |
| 2015-06-23 | Eingeleitet | Canaccord Genuity | Buy |
Alle ansehen
Lipocine Inc Aktie (LPCN) Neueste Nachrichten
What's going on with Lipocine stock on Monday? - MSN
LPCN Downgraded to Neutral by HC Wainwright & Co. | LPCN Stock N - gurufocus.com
What's Going On With Lipocine Stock On Monday? - Benzinga
This Carvana Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday - Benzinga
H.C. Wainwright Downgrades Lipocine(LPCN.US) to Hold Rating - Moomoo
Lipocine Inc. Shareholders Are Encouraged to Reach Out to - globenewswire.com
LPCN stock crashes 78%—here’s why - MSN
Lipocine’s Phase 3 Trial Failure Triggers Stock Drop, Strategic Reevaluation - timothysykes.com
Lipocine Faces Market Setback as LPCN 1154 Fails Key Trial - StocksToTrade
LPCN Should I Buy - Intellectia AI
Lipocine Stock Plummets After Clinical Trial Disappointment - StocksToTrade
Lipocine Stock Plunges After LPCN 1154 Misses Phase 3 Primary Endpoint - Sahm
Crude Oil Rises Sharply; Acuity Shares Fall After Q2 Results - Sahm
Nasdaq Down 1%; US Initial Jobless Claims Fall - Sahm
Lipocine Inc (ticker: LPCN) announced that its experimental drug for postpartum depression failed to meet the primary endpoint in its Phase III clinical trial, causing the company's stock price to plummet by 78.4% in pre-market trading. - Bitget
Lipocine Tumbles 78.6% Intraday: Is This A Volatility Shock or a Reckoning? - Bitget
LPCN | Lipocine Inc. Insider Trading - Quiver Quantitative
CEO Mahesh Patel Acquires 25,000 Shares of Lipocine Inc (LPCN) - GuruFocus
Lipocine CEO buys 25,000 shares in open market | LPCN Insider Trading - Stock Titan
Oral ‘roid void in PPD? Lipocine MINI bike may have wheels - BioWorld MedTech
LPCN Stock Crashes 78%— Here’s Why - Stocktwits
Lipocine weighs path after LPCN 1154 Phase 3 miss - TipRanks
Phase 3 PPD trial for Lipocine (NASDAQ: LPCN) drug falls short - Stock Titan
Lipocine stock tumbles after phase 3 trial misses endpoint - investing.com
Lipocine's postpartum depression pill misses main goal in late-stage study - TradingView
Lipocine reports topline safety & efficacy results for LPCN 1154 in patients with postpartum depression - marketscreener.com
Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with Postpartum Depression - Bitget
Retail Trends: Can Lipocine Inc deliver consistent EPS growth2026 Recap & Real-Time Volume Spike Alerts - baoquankhu1.vn
Will Lipocine's LPCN 1154 Set A New Standard In Postpartum Depression? - RTTNews
Gains Recap: Is Lipocine Inc a cyclical or defensive stockQuarterly Performance Summary & Weekly Stock Performance Updates - baoquankhu1.vn
Aug Mood: What is the Moat Score of Lipocine IncMarket Sentiment Summary & Daily Entry Point Trade Alerts - baoquankhu1.vn
Lipocine (NASDAQ:LPCN) Rating Increased to Hold at Wall Street Zen - MarketBeat
If You Invested $1,000 in Lipocine Inc (LPCN) - Stock Titan
LPCN Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Lipocine price target raised to $11 from $6.75 at Alliance Global - TipRanks
Lipocine Announces 2025 Financial Results and Progress on Postpartum Depression, Epilepsy, and Obesity Drug Pipeline - Minichart
Lipocine Inc. 2025 Annual Report: Innovative Oral Drug Delivery, CNS & Metabolic Pipeline, and R&D Highlights - Minichart
Lipocine Announces Financial Results for the Full Year Ended December 31, 2025 - The Herald Journal
Lipocine Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Lipocine 2025 Financial Results: Q4 & Annual PerformanceNews and Statistics - IndexBox
Lipocine: Fourth Quarter Financial Results Overview - Bitget
Lipocine: Q4 Earnings Snapshot - Barchart
Lipocine (NASDAQ: LPCN) 2025 revenue falls to $2M with $9.6M loss - Stock Titan
LPCN: 2025 saw a net loss of $9.6M as revenue fell, with cash runway through Q1 2027 and ongoing R&D focus - TradingView
Lipocine 10-K: Revenue $2.0M, EPS (Basic) $(1.77) - TradingView
Lipocine Inc expected to post a loss of 61 cents a shareEarnings Preview - TradingView
Is Lipocine Inc affected by consumer sentiment2026 Performance Recap & Weekly Setup with High ROI Potential - baoquankhu1.vn
AI Stocks: Will Lipocine Inc benefit from rate cuts2025 Support & Resistance & Daily Profit Maximizing Tips - baoquankhu1.vn
Lipocine Stock Quote, Share Price, News and Analysis - Longbridge
Lipocine Files Prospectus to Enable $50M Stock Offering - The Globe and Mail
Lipocine (LPCN) Expected to Announce Earnings on Thursday - Defense World
Finanzdaten der Lipocine Inc-Aktie (LPCN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):